There are 2789 resources available
525P - Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
Presenter: Meredith Mckean
Session: ePoster Display
526P - Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3
Presenter: Pavani Chalasani
Session: ePoster Display
527P - Phase I study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) or liver metastases (LM)
Presenter: Debashis Sarker
Session: ePoster Display
749P - Cardiotoxicity in patients treated with PARP-inhibitors
Presenter: Mariola Blanco Clemente
Session: ePoster Display
750P - Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity
Presenter: Simona Manacorda
Session: ePoster Display
751P - Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
Presenter: Pauline Corbaux
Session: ePoster Display
752P - PARP-inhibitors beyond progression: A new way to manage oligometastatic ovarian cancer recurrence
Presenter: Eleonora Palluzzi
Session: ePoster Display
753P - Adverse events experienced by patients in the placebo arm of maintenance therapy trials in advanced ovarian cancer
Presenter: Sandy Simon
Session: ePoster Display
754P - Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer in Japan - GOTIC-019: A multi-institutional retrospective cohort study
Presenter: Shoji Nagao
Session: ePoster Display
755P - A machine learning approach applied to gynaecological ultrasound to predict progression-free survival in ovarian cancer patients
Presenter: Francesca Arezzo
Session: ePoster Display